SRPT
Sarepta Therapeutics, Inc.
SRPT lost money over the past year, so it has no meaningful PE right now. Analysts expect a turn to a loss, though they disagree widely on how much.
SRPT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Healthy | |
| Weak |
SRPT's cash flow is currently healthy, and its profitability is stable, but its revenue and balance sheet are under pressure.
SRPT PE Valuation
SRPT has no meaningful PE right now: it lost money over the past year.
SRPT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect SRPT's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
SRPT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.37 | +$1.58 |
| Q2 2026 | -$2.90 | -$2.09 |
| Q1 2026 | -$0.96 | +$1.67 |
| Q4 2025 | -$8.44 | -461% |
| Q3 2025 | -$2.95 | -288% |
| Q2 2025 | -$0.81 | -205% |
| Q1 2025 | -$2.63 | -712% |
| Q4 2024 | $2.34 | +$8.14 |
SRPT is still losing money, but far less than before: $1.37 per share over the past year, against $12.69 at its worst in early 2023.
SRPT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $381.4M | -4.5% |
| Q2 2026 | $401.3M | -34% |
| Q1 2026 | $730.8M | -1.9% |
| Q4 2025 | $442.9M | -33% |
| Q3 2025 | $399.4M | -15% |
| Q2 2025 | $611.1M | +68% |
| Q1 2025 | $744.9M | +80% |
| Q4 2024 | $658.4M | +66% |
SRPT's revenue has slid since its 2025 peak: $381M last quarter, down 4.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.4% | +24 points |
| Q2 2026 | 3.3% | -16 points |
| Q1 2026 | 49% | +89 points |
| Q4 2025 | -93% | -118 points |
| Q3 2025 | -26% | -31 points |
| Q2 2025 | 19% | +19 points |
| Q1 2025 | -40% | -49 points |
| Q4 2024 | 25% | +18 points |
SRPT's operating margin was −2.4% last quarter, up 24 points from the same quarter a year ago.
SRPT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $57M | +$94.6M |
| Q2 2026 | $196.5M | -14% |
| Q1 2026 | -$204.8M | +$422.3M |
| Q4 2025 | $127.6M | +136% |
| Q3 2025 | -$37.5M | +$70.4M |
| Q2 2025 | $229.5M | +$243.8M |
| Q1 2025 | -$627.1M | -$352.6M |
| Q4 2024 | $54M | +$127.7M |
SRPT's free cash flow has turned positive after six years mostly in the red: $176M over the past year.
SRPT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +499K shares |
| 1 year | +5.7% | +5.7M shares |
| 3 years | +19% | +17M shares |
| 5 years | +36% | +28M shares |
SRPT has 106M diluted shares, up 5.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
SRPT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 89.5x | High |
| Q2 2025 | -12.7x | Net Cash |
| Q4 2024 | 0.1x | Very low |
| Q3 2024 | 8.6x | High |
| Q2 2024 | 10.8x | High |
SRPT's net debt is more than 20 years of its operating earnings (EBITDA), up from 11 years a year ago.
SRPT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.3 | Neutral |
| Stochastic | 26.2 | Neutral |
SRPT's weekly RSI is 42 (neutral) and its Stochastic is 26 (neutral).
SRPT PE vs Healthcare Sector
| Metric | SRPT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SRPT has no meaningful PE right now: it lost money over the past year.
SRPT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.7 | 9.3% below |
| 20 week MA | $18.2 | 12% below |
| 50 week MA | $18.9 | 15% below |
| 100 week MA | $35.3 | 55% below |
| 200 week MA | $78.9 | 80% below |
SRPT is in a downtrend: it's below all five of its weekly moving averages, and 80% below its 200-week average.
SRPT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $129.8 | $175.0 | +35% |
| 2021 | $175.0 | $91.6 | -48% |
| 2022 | $91.6 | $130.0 | +42% |
| 2023 | $130.0 | $96.4 | -26% |
| 2024 | $96.4 | $121.5 | +26% |
| 2025 | $121.5 | $22.1 | -82% |
| 2026 YTD | $22.1 | $16.0 | -28% |
SRPT has finished lower in three of the last six years. It's down 28% so far in 2026.